EMA — authorised 28 July 2006
- Application: EMEA/H/C/000630
- Marketing authorisation holder: Warner Chilcott Deutschland GmbH
- Local brand name: Livensa
- Indication: Livensa is indicated for the treatment of hypoactive sexual desire disorder (HSDD) in bilaterally oophorectomised and hysterectomised (surgically induced menopause) women receiving concomitant estrogen therapy.
- Status: withdrawn